Similar to NPM1::ALK, another form of chimeric ALK involving clathrin (CLTC::ALK) which is expressed in a distinct subtype of B-cell lymphoma displaying plasmablastic cell morphology and immunophenotype, is also highly responsive to the next generation ALK inhibitors (47), further highlighting the potent oncogenic role of chimeric ALK, regardless of the T- vs. B-cell lineage of the transformed lymphocytes (Figures 1, 2). Here, ALK is linked to B-cell non-Hodgkin lymphoma.